Syncona CEO On Why Its 10th Start-Up Focuses On T-Regulatory Cell Therapies

21 May 2019

• By Sten Stovall

UK investment group Syncona Ltd has financed its tenth start-up, Quell Therapeutics, with the aim of developing engineered T regulatory (Treg) cell therapies.

T cells — Syncona founded Quell Therapeutics with £35m Series A Financing • Source: Shutterstock

With the founding of Quell Therapeutics via a £35m series A financing, Syncona Ltd has created its tenth biotech start-up since its own foundation in 2012 and the investment group says other novel corporate launches can still be expected.

Quell Therapeutics, a new cell therapy company, was founded on 20 May with £34m provided by Syncona and a further...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

AbbVie Licenses IGI’s ISB 2001 In Second Myeloma Trispecific Deal For 2025

10 Jul 2025

• By Alaric DeArment

IGI CEO Cyril Konto said in an interview that his company picked AbbVie for its agility, drug development acumen and expertise in areas like intellectual property and legal affairs.

Merck & Co. Remains In The BD Game After Verona Takeout

10 Jul 2025

• By Jessica Merrill

CEO Rob Davis said the company is in pursuit of more deals as it looks to close the revenue gap looming from the loss of Keytruda in 2028.

Asia Deal Watch: JXR And Alexion Build Upon Existing Gene Therapy Alliances

10 Jul 2025

• By Joseph Haas, Lisa Takagi, Sushmita Panda, and Anju Ghangurde

Plus deals involving TandemAI/Perpetual Medicines, Biocytogen/BeOne, Chugai/Gero, CStone/Istituto Gentili, Alembic/Utility, Brii/Joincare, HanchorBio/Henlius, Rakuten/Cyntec and more.